medigraphic.com
ISSN 0188-2198 (Print)

2008, Number 1

<< Back Next >>

Rev Mex Cardiol 2008; 19 (1)

Clinical benefit of prolonged liberation nifedipine in a cohort of Mexican diabetic hypertensive patients

Rubio GAF, García GC, Rodríguez RF

Language: Spanish
References: 16
Page: 16-20
PDF size: 98.66 Kb.


ABSTRACT

Diabetes occurs in 46% of hypertensive patients in Mexico. This association enhances up to 4 times the risk of a cardiovascular event. Objective: To determine the effectiveness, safety and tolerability of slow release nifedipine in mexican hypertensive diabetic patients. Methods: A 12-week, farmacosurveillance study was conducted in the offices of mexican general practitioners. All patients received slow-release nifedipine, they returned for follow-up visits at weeks 4, 8 and 12 of therapy. All diabetic patients previously or newly diagnosed with mild-to-moderate essential hypertension were included and received slow release nifedipine. Results: After twelve weeks, 514 patients were eligible for efficacy analysis, in them BP went down from 167 ± 20.8/ 100.2 ± 11.4 mmHg to 136.6 ± 13.4/84.1 ± 6.7 mmHg. Sitting heart rate (HR) was 83.9 ± 11.2 beats per minute (bpm) at the beginning, and it was 78.0 ± 7.7 bpm 12-weeks later. 38.5% of patients lowered blood pressure ‹ 130/85 with 30 mg of the drug. Each of the differences was statistically significant (p ‹ 0.001). Tolerability of both presentations of nifedipine was good in 87% of the patients. Conclusion: In Mexican diabetic antihypertensive patients slow-release nifedipine showed good antihypertensive efficacy, and treatment was associated with a low incidence of adverse events.


REFERENCES

  1. Velázquez O, Rosas M, Lara A y cols. Prevalencia e interrelación de enfermedades crónicas no transmisibles y factores de riesgo cardiovascular en México. Arch Cardiol Mex 2003; 73: 62-77.

  2. Rubio AF, Lozano JJ, Vargas G, Rodríguez L, Garrido H. Manejo de la hipertensión arterial en el paciente con diabetes mellitus. La evidencia a raíz de los grandes ensayos clínicos. Med Int Mex 2002; 18: 195-199.

  3. Kaplan NM. Management of hypertension in patients with type 2 diabetes mellitus: Guidelines based on current evidence. Ann Intern Med 2001; 135: 1079-1083.

  4. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-713.

  5. Guidelines Committee. 2003 European Society of Hypertension- European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-1053.

  6. The seven report of the Joint National Committee on detection, evaluation and treatment of high blood pressure. JAMA 2003; 289: 2560-2572.

  7. Rubio AF, García C, Rodríguez F. La eficacia y la tolerabilidad del nifedipino de liberación osmótica en pacientes hipertensos mexicanos. Med Int Mex 2004; 20: 38-42.

  8. American Diabetes Association. Hypertension management in adults with diabetes. Diabetes Care 2004; 27: S65-S67.

  9. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004; 27: S5-S10.

  10. Tuomilehto J, Rastenyte D, Birkenhager WH et al, for the Systolic Hypertension in Europe (Syst-Eur) trial Investigators. Effect of calcium- channel blockade in older patients with diabetes ans systolic hypertension. N Engl J Med 1999; 340: 677-684.

  11. Fogari R, Zoppi A, Carradi L et al. Long-term effects of ramipril and nitrendipine on albuminuria in hypertensive patients with type II diabetes and impaired renal function. J Hum Hypertens 1999; 13: 47-53.

  12. Rubio AF, Treviño CJ, Vargas G, Arceo A, Lozano JJ, Rodríguez L. Renoprotective effects of the combination trandolapril/verapamil in patients with type 2 diabetes mellitus and hypertension. Clin Drug Invest 2002; 22: 541-546.

  13. Kaasjager KA, Koomans HA, Rabelink TJ. Effectiveness of enalapril versus nifedipine to antagonize blood pressure and the renal response to endothelin in humans. Hypertension 1995; 25: 620-625.

  14. Rubio AF, Arceo A, Vargas G, Rodríguez L, Lozano JJ, Treviño C. The effect of trandolapril and its fixed-doser combination with verapamil on proteinuria in normotensive adults with type 2 diabetes. Diabetes Care 2004; 27: 1688-1691.

  15. Barron JJ, Al-Zakwani I, Iarocci T. Quality of care and attributable healthcare costs in diabetic hypertensive patients initiated on calcium antagonist therapy. Clin Drug Invest 2004; 24: 641-649.

  16. Fernández R, Puig JC, Rodríguez JC, Garrido J, Redon J. Effect of two antihypertensive combinations on metabolic control in type-2 diabetic hypertensive patients with albuminuria: a randomized double-blind study. J Hum Hypertens 2001; 15: 849-856.




2020     |     www.medigraphic.com